Squarepoint Ops LLC Purchases 25,829 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Squarepoint Ops LLC increased its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 142.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,022 shares of the company’s stock after acquiring an additional 25,829 shares during the period. Squarepoint Ops LLC owned about 0.08% of Apogee Therapeutics worth $1,732,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Arizona State Retirement System grew its holdings in shares of Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock worth $236,000 after purchasing an additional 258 shares during the last quarter. EntryPoint Capital LLC lifted its position in Apogee Therapeutics by 44.7% during the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock worth $133,000 after buying an additional 617 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after acquiring an additional 1,340 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Apogee Therapeutics by 28.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,155 shares of the company’s stock valued at $475,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Apogee Therapeutics by 111.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock worth $274,000 after acquiring an additional 2,172 shares during the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.

Apogee Therapeutics Price Performance

APGE opened at $54.48 on Friday. The stock has a market capitalization of $3.18 billion, a P/E ratio of -10.77 and a beta of 2.74. The company’s 50 day simple moving average is $49.58 and its 200-day simple moving average is $49.54. Apogee Therapeutics, Inc. has a one year low of $14.19 and a one year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.60) EPS for the quarter, meeting analysts’ consensus estimates of ($0.60). As a group, analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 EPS for the current year.

Insider Buying and Selling

In other Apogee Therapeutics news, CFO Jane Henderson sold 6,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $48.26, for a total transaction of $289,560.00. Following the transaction, the chief financial officer now directly owns 200,871 shares in the company, valued at approximately $9,694,034.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Apogee Therapeutics news, CFO Jane Henderson sold 6,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $48.26, for a total transaction of $289,560.00. Following the completion of the sale, the chief financial officer now owns 200,871 shares in the company, valued at approximately $9,694,034.46. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Carl Dambkowski sold 6,665 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $56.26, for a total value of $374,972.90. Following the completion of the transaction, the insider now owns 274,128 shares in the company, valued at $15,422,441.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 146,665 shares of company stock worth $7,058,635 over the last three months. 36.10% of the stock is currently owned by company insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.